NL-OMON35823已完成不适用
A Phase I open-label study to investigate the mass balance and biotransformation of a single oral 160 mg (100 µCi) dose of 14C-MDV3100 (ASP9785) in healthy male subjects - [14C]- MDV3100 tracer label study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Healthy male subjects
- •-18 to 55 years inclusive.
- •-BMI 18.5 to 30.0 kg/m2
- •-Non-smoker, or not more than 10 cigarettes for at least three months before drug administration
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 12 months prior the start of this study. Participation is also not permitted when participated in more than 3 other drug studies in the 10 months prior to the start of this study.
研究者
相似试验
已完成
不适用
A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE MASS BALANCE AND PHARMACOKINETICS OF [14C]-IMU-838 IN HEALTHY MALE SUBJECTSMultiple SclerosisNL-OMON51590Immunic AG7
进行中（未招募）
1 期
OP-724-001 studyHealthy volunteersJPRN-jRCT2031230432Yuushi Haruyama6
已完成
不适用
Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism And Excretion Of [14C]-Etripamil Nasal Spray After a Single Dose to Healthy Male Subjects.NL-OMON50057Milestone Pharmaceuticals Inc8
已完成
1 期
A mass-balance study of [14C]KDT-3594 in healthy adult maleHealthy conditionJPRN-jRCT2071220057Shimizu Yoshitaka8
进行中（未招募）
1 期
A study to investigate the uptake, distribution, breakdown and excretion of a single dose of [14C]-etripamil administered with a nasal spray in healthy volunteersParoxysmal supraventricular tachycardia (PSVT)EUCTR2019-004979-39-NLMilestone Pharmaceuticals Inc.8